Virax Biolabs Group Limited, a pioneering biotech entity specializing in immune response detection and viral disease diagnostics, has announced the formation of a non-exclusive distribution alliance with Tebubio, a French enterprise, to extend the reach of its ImmuneSelect Research Use collection throughout the European Union, as well as Norway and Switzerland.
“We’re thrilled to introduce this partnership with Tebubio, who will be vital in enhancing accessibility for ImmuneSelect within Europe’s significant market,” stated James Foster, CEO of Virax Biolabs. “This agreement bolsters our ongoing mission to advance immune profiling technologies and addresses the growing need for in-depth analysis of immune health through ImmuneSelect.”
“Partnering with Virax is a momentous occasion for us as it highlights our dedication to advancing diagnostic innovations like ImmuneSelect,” said Romain Cordonnier-Goulay, CSO of Tebubio. “Our robust distribution channels and connections throughout Europe will ensure that ImmuneSelect reaches a wide array of research clientele to assist them with their investigative endeavors.”
ImmuneSelect encompasses a suite of research tools tailored for exploring adaptive immunity. Products under the ImmuneSelect label are strictly for research and investigational uses and are not intended for diagnostic purposes. The ImmuneSelect line features peptide libraries encompassing epitopes from pathogens designed to stimulate T cell activity. Initial offerings include pools for SARS-CoV-2, SARS-CoV-2 MHC-1 (“CD8”), Lyme disease, cytomegalovirus (CMV), respiratory syncytial virus (RSV), and Epstein-Barr Virus (EBV), with the collection continuously expanding. ImmuneSelect’s Recombinant Antibodies target cytokines and biomarkers, available in various forms designed for applications such as Flow Cytometry, ELISA, and ELISpot/Fluorospot. ImmuneSelect is cost-effective, user-friendly, and works seamlessly with standard lab equipment.
Virax Biolabs Group Limited stands at the forefront of detecting immune responses and diagnosing viral diseases, concentrating on developing T-Cell-based testing technologies to establish a comprehensive immunological profiling system. T-Cell assays prove particularly useful for diagnosing and treating post-viral conditions like long Covid and other chronic disorders related to immune frailty.
Tebubio supports life science research every day, aiding in the quest for scientific advancement for a brighter tomorrow. With local offices throughout Europe, Tebubio backs life science and biotechnology researchers with an integrated range of solutions to help accelerate the progress of their projects.